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Introduction: Intra-articular glucocorticoid treatment (IAGC) is widely used for symptom relief in arthritis. However,
knowledge of factors predicting treatment outcome is limited. The aim of the present study was to identify
response predictors of IAGC for knee synovitis in patients with rheumatoid arthritis (RA).
Methods: In this study 121 RA patients with synovitis of the knee were treated with intra-articular injections of
20 mg triamcinolone hexacetonide. They were followed for six months and the rate of clinical relapse was studied.
Non-responders (relapse within 6 months) and responders were compared regarding patient characteristics and
knee joint damage as determined by the Larsen-Dale index. In addition, matched samples of serum and synovial
fluid were analysed for factors reflecting the inflammatory process (C-reactive protein, interleukin 6, tumour
necrosis factor alpha, vascular endothelial growth factor), joint tissue turnover (cartilage oligomeric matrix
protein, metalloproteinase 3), and autoimmunity (antinuclear antibodies, antibodies against citrullinated peptides,
rheumatoid factor).
Results: During the observation period, 48 knees relapsed (40%). Non-responders had more radiographic joint
damage than responders (P = 0.002) and the pre-treatment vascular endothelial growth factor (VEGF) level in
synovial fluid was significantly higher in non-responders (P = 0.002).
Conclusions: Joint destruction is associated with poor outcome of IAGC for knee synovitis in RA. In addition, higher
levels of VEGF in synovial fluid are found in non-responders, suggesting that locally produced VEGF is a biomarker
for recurrence of synovial hyperplasia and the risk for arthritis relapse.Introduction
Intra-articular glucocorticoid treatment (IAGC) has
been used in the treatment of arthritis disorders for de-
cades. Glucocorticoid injection therapy is still frequently
used, as signs and symptoms of synovitis can be rapidly
and effectively controlled. However, despite long expe-
rience there are few investigations dealing with factors
influencing the treatment outcome.
The choice of steroid preparation [1], the accuracy of
the injection placement [2], the synovial fluid aspiration
[3] and the immobilisation of weight-bearing joints [4]* Correspondence: tomas.weitoft@lg.se
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stated.have all been identified as factors with an impact on
treatment outcome. Those factors can be controlled
using correct injection routines in the daily clinical prac-
tice. A successful treatment result after two weeks has
also been shown to predict a favourable response at six
months [5].
However, several factors, such as disease activity, de-
gree of joint destruction, the character of the local in-
flammatory process and the autoimmune profile, have
also been considered to be important for treatment out-
come. Most investigations are small and differences in
study design and outcome measures preclude firm con-
clusions. A high proportion of polymorphonuclear cells
in synovial fluid [6] and macrophages in synovial biop-
sies [7] have been reported to be associated with a betterLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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knee.
Recently the Danish CIMESTRA study [8] observed a
significant, but weak association, not only between the
outcome of IAGC and joint erosion score for wrists
using magnetic resonance imaging (MRI), but also for
the presence of antibodies against citrullinated peptides
(anti-CCP) in serum.
The aim of the present investigation was to identify
patient or disease characteristics including biochemical
variables analysed in synovial fluid and blood that may
influence the long-term effect of intra-articular gluco-
corticoid therapy for knee synovitis in RA.
The results may be clinically important as patients at
risk for early arthritis relapse could benefit from an extra
careful and strict injection procedure and a better follow
up regimen.
Methods
At the outpatient rheumatology departments at the hos-
pitals in Gävle, Uppsala and Falun, Sweden, patients with
rheumatoid arthritis (RA) [9] and signs and symptoms
of synovitis of the knee were invited to participate in
the study. Patients with an interval <3 months since
the latest injection, oral corticosteroid treatment corre-
sponding to 10 mg prednisolone daily or more, and pa-
tients in function class 4 according to Steinbrocker [10]
were excluded.
Information on patient characteristics (age, sex, body
weight, disease duration, smoking habits and concomi-
tant treatments) was collected and serum samples were
drawn. The level of disability was evaluated using the
Swedish version of the Health Assessment Questionnaire
(HAQ) [11]. The number of tender and swollen joints
were counted and the disease activity score (DAS28)
[12] was calculated. Using a lateral approach the joint
was entered with a 0.7 × 40 mm needle. As much as
possible of the synovial fluid was aspirated and saved for
analysis. A dose of 20 mg triamcinolone hexacetonide
(THA) was injected. After treatment the patients were
recommended a 24-hour post-injection rest at home.
Within a two-month period after injection a radiological
examination of the knee was performed and the radio-
graphs were graded on a scale from 0 to 5 (0 = normal,
5 = severe changes) according to Larsen-Dale [13] by a
single independent radiologist. For patients with IAGC
in both knees during the study period, only the first in-
jection was included in the study.
The patients were told to contact the rheumatology
department if symptoms from the treated knee recurred.
If so, the knee was examined again and if the pain or
discomfort was associated with signs of clinical synovitis
(tenderness and swelling) the time to relapse was regis-
tered and the patient was defined as a non-responder.The patients had follow up visits according to the cli-
nical routines. All patients received a phone call at the
end of the six-month observation period to confirm that
no unregistered relapse had occurred.
Serum and synovial samples were centrifuged for
20 minutes at 1800 g within one hour and were then
stored at -70°C until analysis.
The study was approved for each participating center
(Gävle, Uppsala and Falun) by The Regional Ethical
Review Board in Uppsala and all patients gave their in-
formed consent.
Laboratory methods
All analyses were performed without knowledge of the
clinical outcome. The local inflammatory process was
evaluated using white blood cell count of polynuclear and
mononuclear cells, metalloproteinase 3 (MMP 3), tumour
necrosis factor alpha (TNF), interleukin 6 (IL6) and vas-
cular endothelial growth factor (VEGF) in synovial fluid.
The four latter markers were analysed by commer-
cial sandwich ELISA kits (DY206, DY 513, DY210 and
DY293B, R&D Systems, Minneapolis, MN, USA).
Systemic inflammation and clinical disease activity were
assessed by analysing serum levels of C-reactive protein
(CRP), TNF, IL6, VEGF and MMP3 and calculations of the
DAS28 index. CRP (reagent: 6 K2601) was analysed on an
Architect Ci8200 analyser (Abbott Laboratories, Abbott
Park, IL, USA).
The activity of the destructive process was assessed
using analyses of serum and synovial fluid levels of the
cartilage oligomeric matrix protein (COMP) and the
proteolytic enzyme MMP3. COMP was analysed using a
sandwich ELISA (Anamar, Lund, Sweden). The detection
limit of the assay is <0.1 U/L, and its intra-assay and
interassay coefficient is <5%.
The autoimmune profile of the disease was analysed
using serum levels of antinuclear antibodies (ANA; Immu-
noConcept; Sacramento, CA, USA, screening titer 1:200,
corresponding to 95% specificity among 100 healthy con-
trols), anti-CCP and the immunoglobulin M (IgM) sub-
class of Rheumatoid Factor (RF). Anti-CCP and RF were
investigated with an enzyme immuno assay using a Phadia
Immunocap system, Uppsala, Sweden. For anti-CCP a
level of 7 arbitrary units, and for RF a level of 5 IU/ml,
were regarded as positive. When investigating 100 healthy
blood donors, all individuals were anti-CCP negative
whereas 4% were RF positive using these cut-offs.
Statistical methods
The results from patients with relapse within six months
(non-responders) were compared with responders using
statistical analysis with the T-test for independent values,
Mann-Whitney U–test or Chi2-test when appropriate.
Correlation between variables was assessed by Spearman’s
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sion model with treatment response as the dependent
variable was fitted using stepwise backwards elimination
of independent variables based on likelihood ratio tests.
To adjust for multiple comparisons of biomarkers, Šidák
correction of the significance level was performed. Cor-
recting of a family wise error rate of 0.05 for 17 compari-
sons gives an adjusted significance level equal to 0.003.
The statistical calculations were made using the com-
puter software program IBM SPSS Statistics version 21.
Results
A total of 121 patients fulfilled the inclusion criteria and
were eligible for the study and all of them could be
followed for six months. The patient characteristics are
presented in Table 1.
Most patients (89%) were using disease modifying anti-
rheumatic drugs (DMARD). In all, 74 patients were
treated with methotrexate alone or in combination with
other DMARD, and biological agents were used by 24 par-
ticipants. There was no significant difference in phar-
macotherapy between the groups at baseline. During the
observation period 22% of responders and 14% of non-
responders changed their DMARD therapy (P = 0.189).
Oral glucocorticoids were used by 44% of the patients.
There was no significant difference in treatment outcome
between the subgroups with and without oral glucocorti-
coids (P = 0.265). Furthermore, there was no significant
difference in number of additional IAGC treatments given
for other joints (24 and 16 joints, respectively) between re-
sponders and non-responders during the observation
period (P = 0.374).
Thirty-nine patients had never had a knee joint injection
before and their responses to IAGC were similar to other
patients (data not shown). A total of 73 of the 121 patients
(60%) had no relapse during the six-month observation
period (responders). The shortest time to relapse in theTable 1 Patient characteristics
Analysis All (n = 121) Respon
Age, mean (years) 60.5 ± 14.0 58
Sex (M/F) 31/90
Current smoking 19/121 (16%) 11/
RA duration, median (years) 10 (0 to 60) 11
Weight, mean (kg) 73.1 ± 16.4 72
HAQ index, mean 1.07 ± 0.64 1.0
DAS28 index, mean 4.40 ± 1.20 4.5
CRP, median (mg/L) 10.8 (0.1 to 159) 12.9
Larsen-Dale index, mean 1.50 ± 1.3 1
Synovial fluid, median (ml) 10 (0 to 105) 8 (
Mean ± SD, Median (range), Bold figures: P <0.003. CRP, C-reactive protein; DAS28, dise
M, male; n, number; RA, rheumatoid arthritis; SD, standard deviation.study was five days. In eight cases recurrence of knee
symptoms was not associated with clinical synovitis. Mean
duration to relapse in the non responding group was
88 ± 49 days and the participants in this group were older
and had significantly more joint destruction in the knee
(Table 1). Age and disease duration correlated to radio-
graphic destruction (rho: 0.277, P: 0.003 and rho: 0.342,
P: <0.001, respectively). The results of the laboratory
analyses of serum samples are presented in Table 2. No
significant differences between responders and non-
responders for the analysed serum variables were found.
Synovial fluid was available from 105/121 knees (87%)
with no significant difference between groups. However,
the effusion volumes were significantly larger for non-
responders than for responders (Table 1). The level of
VEGF in synovial fluid was significantly higher in non-
responding patients (Table 3, Figure 1) and correlated sig-
nificantly with IL6 levels in the synovial fluids (rho: 0.386;
P: <0.001). No other differences between the groups were
found. The results of the laboratory analysis of synovial
fluid samples are presented in Table 3. After logistic
regression analysis the findings for the Larsen-Dale score
and VEGF in synovial fluid in relation to response
remained.
Serum levels of TNF were only detectable in 35% and
IL6 in 50% of the cases. Compared with serum, the syn-
ovial fluid levels of TNF, IL6, MMP3, COMP and VEGF
were all significantly higher (P <0.001) (data not shown).Discussion
The main finding in the present study is that non-
responders had more joint destruction and higher levels
of VEGF in synovial fluid than responders. Neither the
autoimmune profile, the ongoing cartilage turnover nor
local or systemic inflammation seems to influence the
relapse rate.ders (n = 73) Non-responders (n = 48) P-value
.2 ± 14.8 64.0 ± 11.9 0.023
19/54 12/36 0.899
73 (15%) 8/48 (17%) 0.813
(0 to 60) 8 (0 to 40) 0.60
.1 ± 16.2 74.8 ± 16.8 0.375
8 ± 0.67 1.05 ± 0.60 0.791
3 ± 1.22 4.21 ± 1.52 0.145
(0.2 to 159) 9.4 (0.7 to 119) 0.14
.2 ± 1.06 1.9 ± 1.45 0.002
0 to 105) 16.5 (0 to 75) 0.006
ase activity score in 28 joints; F, female; HAQ, Health Assessment Questionnaire;
Table 2 Serum analysis
Analysis All (n = 121) Responders (n = 73) Non-responders (n = 48) P-value
s-TNF (pg/mL) 0 (0 to 1,212) 0 (0 to 1,212) 0 (0 to 99) 0.399
s-IL6 (pg/mL) 14 (0 to 324) 30 (0 to 24) 7 (0 to 324) 0.629
s-VEGF (pg/mL) 218 (0 to 1,750) 218 (0 to 1,188) 212 (0 to 1,750) 0.850
s-MMP3 (pg/mL) 138 (16 to 116,714) 138 (16 to 116,714) 140 (34 to 52,031) 0.911
s-COMP (U/L) 10.7 ± 3.4 10.8 ± 3.9 10.5 ± 2.5 0.636
s–anti-CCP (>7 IU/ml) 87/121 (72%) 48/73 (66%) 39/48 (81%) 0.064
s-IgM-RF (>5 IU/ml) 90/121 (74%) 51/73 (70%) 39/48 (81%) 0.160
s-ANA 38/99 (38%) 14/39 (36%) 24/60 (33%) 0.682
Median (range), mean ± SD. ANA, antinuclear antibodies; anti-CCP, anti-cyclic citrullinated peptide; COMP, cartilage oligomeric matrix protein; IgM, immunoglobulin
M; MMP3, matrix metalloproteinase 3; RF, rheumatoid factor; s, serum; VEGF, vascular endothelial growth factor.
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several possible outcome predictors of IAGC for knee syno-
vitis. Many previous outcome investigations include patients
with different diagnoses. As different joints and different
rheumatic diseases may have different predictors, in this
study we have focused on knee injections in RA patients.
Smoking has been identified as an exogenous factor of
importance in the pathogenesis of RA. Furthermore,
treatment with methotrexate and biological agents is less
successful in smokers [14], but results in the present
study indicate that smoking has no influence on the out-
come of IAGC in RA.
Postinjection rest of weight-bearing joints has been
shown to improve the response to IAGC in arthritis (4),
but our findings show that the body weight itself did not
differ between responders and non-responders.
In a randomised controlled trial Jahangier et al. [7] com-
pared knee injections with the combination of yttrium-
90 + 20 mg THA with the combination of placebo +
20 mg THA on 66 patients with different arthritides. The
overall response rate was 48% and no significant difference
between the groups was found at six months. Pretreat-
ment synovial biopsies showed significantly more synovial
macrophages in patients responding on IAGC. Further-
more, Luukiainen et al. [6] studied 30 RA patients with
knee synovitis after IAGC with 30 mg THA and found aTable 3 Synovial fluid analysis
Analysis All (n = 105) Responde
sf-TNF (pg/mL) 42 (0 to 1,128) 51 (0 t
sf-IL6 (pg/mL) 734 (0 to 10,000) 636 (0 t
sf-VEGF (pg/mL) 778 (128 to 2,518) 622 (128
sf-MMP3 (pg/mL) 5,367 (64 to 143,896) 6,696 (64
sf-COMP (U/L) 58.5 ± 36.0 54.4 ±
sf-Mono (x109/L) 1.7 (0 to 132.6) 1.9 (0 t
sf-Poly (x109/L) 1.65 (0 to 32.1) 1.6 (0
Median (range), mean ± SD, Bold figures: P <0.003. COMP, cartilage oligomeric matr
sf, synovial fluid; VEGF, vascular endothelial growth factor.significant correlation between polymorphonuclear leuco-
cytes in synovial fluid and reduction of joint circum-
ference after six months. This parameter had no influence
on the relapse rate in our study.
The CIMESTRA study [8] was designed as a rando-
mised controlled trial on recent onset RA with intense
IAGC (14 mg betamethasone for each knee injection)
combined with either cyclosporine A and methotrexate or
sulfasalazine and methotrexate. The tight control regimen
used made early detection of arthritis relapse possible. A
48% relapse rate after 200 days was found among the 89
included patients with knee synovitis. In the present inves-
tigation we used 20 mg THA on patients with longer dis-
ease duration (median 10 years) and found a 40% relapse
rate after 180 days and we defined relapse as a request for
another injection confirmed with synovitis on clinical
examination. Despite differences in study design and re-
lapse definition the difference in general relapse rate bet-
ween the studies is small.
The CIMESTRA trial showed that the effect of the first
joint injection had a longer duration than a subsequent in-
jection in the same joint and the presence of anti-CCP
was weakly associated with longer injection survival. This
is not confirmed in our study, which, in contrast, showed
a non-significant trend towards more relapse among the
anti-CCP positive patients.rs (n = 61) Non-responders (n = 44) P-value
o 1,128) 36 (0 to 182) 0.706
o 10,000) 1,062 (0 to 10,000) 0.625
to 2.518) 998 (282 to 1,926) 0.002
to 143,896) 5189 (524 to 72,922) 0.686
27.1 63.6 ± 44.6 0.220
o 132.6) 1.5 (0 to 7.1) 0.208
to 19.5) 1.7 (0 to 32.1) 0.801
ix protein; MMP3, matrix metalloproteinase 3; SD, standard deviation;
Figure 1 Synovial fluid levels of VEGF among responders and non reponders. VEGF, vascular endothelial growth factor.
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with synovial biopsies before and two weeks after IAGC
using 40 mg THA for knee synovitis [15]. The results
showed marked reduction of synovial T-lymphocytes,
TNF, IL1 and VEGF, but no significant change in synovial
vascularity or the expression of VEGF on endothelial
cells. The authors discussed whether this finding was im-
portant for the transient effect of IAGC. This hypothesis
is supported by our finding of significantly higher levels
of VEGF in synovial fluid of non-responders in the
present study.
VEGF is normally produced by synovial cells in response
to hypoxia and proinflammatory cytokines, such as TNF
and IL6 [16]. In accordance, levels of IL6 and VEGF in
synovial fluid correlate strongly in our study. VEGF sti-
mulates the formation of new blood vessels and increases
vascular permeability. This is important for production of
the synovial fluid that represents an ultrafiltrate of plasma
as the synovial membrane lacks basement membranes
towards the synovial cavity. VEGF may also protect syno-
viocytes from apoptosis [17], thereby further contributing
to synovial hyperplasia. The high levels of VEGF in the
synovial fluid of IAGC non-responders in the present
study may have stimulated synovial vascularity and rapid
recurrence of blood perfusion and probably the larger
joint effusion as well. This facilitates recruitment of in-
flammatory cells and may explain the increased risk for
relapse. The fact that this difference in VEGF levelsbetween responders and non-responders was found locally
in the treatment target organ, but not systemically, further
argues for a pathogenetic impact of VEGF in the joints in
steroid-resistant RA patients. The role of sf-VEGF in this
study is in agreement with animal studies on the role of
VEGF in arthritis. VEGF knockout mice showed reduced
pathology and less synovial angiogenesis in both antigen-
induced and collagen-induced models of arthritis [18]. An
anti-VEGF antibody has also been shown to prevent
collagen-induced arthritis and reduced established disease
activity in mice [19]. Antibodies to VEGF receptor 1 have
also been shown to attenuate disease activity in mice [20].
These findings suggest the possibility that local anti-VEGF
administration might be an adjunct therapy to THA in
RA patients with high synovial fluid levels of VEGF.
Compared to synovial fluid, the VEGF levels in serum
are significantly lower and show no difference between
the responder groups, indicating that VEGF levels or
VEGF-associated pathology in the local knee environment
determines treatment outcome. None of the systemic va-
riables analysed seems to be important, suggesting a
limited value of analysing serum samples before IAGC to
predict clinical outcome.
However, in juvenile chronic arthritis a high erythro-
cyte sedimentation rate was correlated with a better re-
sponse to IAGC for knee synovitis [21]. Remission of
synovitis of the knee after IAGC lasted longer, not only
if concomitantly treated with methotrexate, but also with
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ter finding was unexpected and the authors discussed
whether the injection placement in a child is easier
during general anaesthesia.
Not surprisingly, the radiographic changes in our pa-
tients were correlated both with disease duration and
age. For elderly RA patients comorbidity with osteo-
arthritis (OA) cannot be excluded. How these joint dis-
eases interact is not known, and comparing the outcome
of IAGC between OA and RA is difficult because of dif-
ferences in pathogenesis, but in the late stages of both
diseases there are more mechanical than immunological
causes for inflammation. RA patients with severe joint
destruction may, therefore, respond more like patients
with severe OA. A systematic review of outcome predic-
tors in OA [23] concluded that results are not con-
sistent, but some of the reviewed studies suggest that
the presence of effusion and the severity of disease have
an impact on treatment outcome. As in several OA
studies, we found an association between degree of joint
damage on radiographs and outcome of IAGC. This has
never been shown in RA before. COMP levels, however,
did not differ between responders and non-responders,
which suggest that the ongoing cartilage turnover has
only minor effects on the effect of IAGC in RA.
A weakness of the study may be the relapse definition,
based on the complaints of the patient, and a confirming
clinical examination. The patient delay may vary due to
individual thresholds for discomfort, pain and need for
help. On the other hand, this method has been used be-
fore [3,24] and is relevant because it reflects the real life
in clinical practice.
In this investigation we have chosen to use 20 mg
THA, as this is the recommended dose for knee injec-
tions in Sweden. Higher doses are often used, but there
are no published dose finding studies comparing the effi-
cacy of different THA dosages for knee injections, and
consequently, there is a large variation in the tradition of
using THA.
Conclusions
The present study suggests that synovial fluid levels of
VEGF have an impact on treatment outcome. In addition
to radiological joint damage, it is the best predictor of
IAGC outcome for knee synovitis and this finding
deserves further research. A clinical application of our
findings is that RA patients with severe radiographic
joint changes should benefit from extra careful injection
procedures, complete synovial fluid aspirations, strict
postinjection immobilisation and tighter follow up.
Ultrasound-guidance may also improve the injection
outcome, but results are conflicting [25,26].
In patients with relapsing synovitis despite normal ra-
diographs and accurate IAGC, a joint infection shouldbe excluded. If cultures are negative, analysis of VEGF in
synovial fluid might be helpful. Our results suggest that
intra-articular anti-VEGF therapy in the future might be
considered as an adjunct therapy in RA patients with re-
lapsing synovitis and high VEGF levels in synovial fluid.
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